Clovis Oncology (CLVS) : Traders are bullish on Clovis Oncology (CLVS) as it has outperformed the S&P 500 by a wide margin of 21.1% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.28%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.25% in the last 1 week, and is up 21.56% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Clovis Oncology, Inc. is up 18.97% in the last 3-month period. Year-to-Date the stock performance stands at -50.71%. The stock has recorded a 20-day Moving Average of 10.07% and the 50-Day Moving Average is 17.6%.
Clovis Oncology (NASDAQ:CLVS): The stock was completely flat for the day, closing at $17.25 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $17.22, the stock touched an intraday high of $17.29 and a low of $16.74. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $17.25. The total trading volume on Friday was 760,851.
Also, SunTrust Robinson Humphrey initiates coverage on Clovis Oncology (NASDAQ:CLVS) The shares have been rated Buy. The rating by the firm was issued on August 5, 2016.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.